Suchergebnisse - (Person:"Curtin, Nicola")

PubPharm (19)

1

Poly(ADP-ribose) polymerase inhibition : past, present and future

enthalten in: Nature reviews. Drug discovery | 2020

von Curtin, N. | Szabo, C.

2

Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis : Mechanism and Potential Role for PARP Inhibitors

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2016

von Kotsopoulos, I. | Kucukmetin, A. | Mukhopadhyay, A. | +2

3

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

enthalten in: Oncotarget | 2015

von Herriott, A. | Tudhope, S. | Junge, G. | +13

4

PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib

enthalten in: Clinical pharmacology in drug development | 2015

von Wang, D. | Li, C. | Sun, W. | +7

5

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma

enthalten in: Current opinion in oncology | 2014

von Vormoor, B. | Curtin, N.

6

PARP inhibitors for anticancer therapy

enthalten in: Biochemical Society transactions | 2014

von Curtin, N.

7

Therapeutic applications of PARP inhibitors : anticancer therapy and beyond

enthalten in: Molecular aspects of medicine | 2013

von Curtin, N. | Szabo, C.

8

Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies

enthalten in: Haematologica | 2013

von Gaymes, T. | Mohamedali, A. | Patterson, M. | +8

9

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2

enthalten in: Journal of the National Cancer Institute | 2011

von Drew, Y. | Mulligan, E. | Vong, W. | +9

10

Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials

enthalten in: Cancer chemotherapy and pharmacology | 2010

von Zaremba, T. | Thomas, H. | Cole, M. | +2